Teladoc Health (NYSE:TDOC) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Posted by Brian Himes on Oct 30th, 2026

Shares of Teladoc Health, Inc. (NYSE:TDOC – Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $6.46 and traded as high as $6.92. Teladoc Health shares last traded at $6.8720, with a volume of 8,586,863 shares traded.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

Positive Sentiment: Q3 results beat expectations. Teladoc reported a loss of $0.15 per share versus the $0.23 consensus loss, while revenue of approximately $605 million exceeded estimates by about 3.3%. Adjusted EBITDA reached roughly $79 million, near the high end of guidance. Teladoc Q3 loss and revenue results
Positive Sentiment: Cash flow and loss quality improved. Investors responded favorably to stronger free cash flow and adjusted EBITDA, suggesting that Teladoc is making progress on cost control even as revenue declined about 3% year over year. Teladoc stock rebounds as cash flow improves
Positive Sentiment: BetterHelp’s insurance strategy is gaining traction. BetterHelp generated $32 million in insurance revenue during Q3, and management expects the insurance-related business to reach an annualized run rate of at least $200 million. Teladoc also plans to repurchase convertible notes, potentially reducing financial obligations. Teladoc BetterHelp insurance and convertible notes plans
Positive Sentiment: Deutsche Bank raised its price target to $11 from $10 and maintained a Buy rating, reinforcing the bullish reaction to the earnings report. Deutsche Bank Teladoc price target update
Neutral Sentiment: Unusually heavy call-option activity and the stock’s move above its 200-day moving average may amplify momentum, but these are trading signals rather than fundamental improvements.
Negative Sentiment: Forward guidance remains mixed. Full-year revenue guidance of $2.4 billion matched consensus, but the FY 2026 EPS range of negative $0.95 to negative $0.75 brackets consensus at negative $0.81. Q4 revenue guidance also has a midpoint below analyst expectations, while the EPS range is wider and includes results below consensus.
Negative Sentiment: Stifel raised its price target to $6.50 but retained a Hold rating, and Needham reaffirmed Hold. These targets remain well below recent trading levels, highlighting valuation and execution concerns. Stifel Teladoc rating

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TDOC. JPMorgan Chase & Co. upped their price target on shares of Teladoc Health from $8.00 to $10.00 and gave the company a “neutral” rating in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Teladoc Health in a report on Wednesday, August 19th. Stifel Nicolaus boosted their target price on shares of Teladoc Health from $5.50 to $6.50 and gave the stock a “hold” rating in a research report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Teladoc Health in a research report on Thursday. Finally, Citigroup cut their target price on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research note on Monday, August 3rd. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $7.77.

Check Out Our Latest Stock Analysis on Teladoc Health

Teladoc Health Price Performance

The business’s fifty day simple moving average is $6.23 and its 200 day simple moving average is $6.47. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -9.91 and a beta of 2.14.

Teladoc Health (NYSE:TDOC – Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. Teladoc Health had a negative return on equity of 11.52% and a negative net margin of 6.27%. The business had revenue of $605.10 million for the quarter, compared to the consensus estimate of $588.14 million. During the same quarter last year, the business posted ($0.28) EPS. The business’s revenue was down 3.4% on a year-over-year basis. As a group, equities analysts forecast that Teladoc Health, Inc. will post -0.88 EPS for the current fiscal year.

Insider Activity at Teladoc Health

In related news, CEO Charles III sold 17,805 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the sale, the chief executive officer owned 465,535 shares of the company’s stock, valued at $2,839,763.50. This trade represents a 3.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Monaco Asset Management SAM acquired a new position in Teladoc Health during the 2nd quarter valued at about $26,864,000. Counterpoint Mutual Funds LLC lifted its stake in shares of Teladoc Health by 1,017.4% in the 3rd quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider’s stock worth $9,571,000 after acquiring an additional 1,502,488 shares during the period. Quantinno Capital Management LP lifted its stake in shares of Teladoc Health by 128.0% in the 1st quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock worth $14,287,000 after acquiring an additional 1,471,631 shares during the period. Pale Fire Capital SE lifted its stake in shares of Teladoc Health by 74.8% in the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock worth $18,522,000 after acquiring an additional 1,454,288 shares during the period. Finally, Freestone Grove Partners LP bought a new position in shares of Teladoc Health in the second quarter valued at approximately $7,338,000. 76.82% of the stock is owned by institutional investors and hedge funds.

About Teladoc Health

(Get Free Report)

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.